Genmab throws in the towel – won't contest royalties ruling

The Danish biotech firm won’t be seeking a review of its arbitration case against Janssen, which Genmab lost at the beginning of April.

Photo: Tuala Hjarnø / Genmab / PR

Genmab has decided to let the royalties dispute over multiple myeloma treatment Darzalex with its collaboration partner Janssen lie.

In connection with firm’s first quarterly report for 2022, which was released on Wednesday, Genmab reports that it will not seek a review of the ruling, making the arbitration award final.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs